SOLICITATION NOTICE
R -- Consulting Services
- Notice Date
- 7/13/2010
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, Station Support/Simplified Acquisitions, 31 Center Drive, Room 1B59, Bethesda, Maryland, 20892
- ZIP Code
- 20892
- Solicitation Number
- NOI1679920
- Archive Date
- 8/11/2010
- Point of Contact
- Idella M. Simpson, Phone: 301-435-8781
- E-Mail Address
-
simpsoi@nida.nih.gov
(simpsoi@nida.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- This is a notice of intent, not a request for a proposal. A solicitation document will not be issued and proposals will not be requested. The National Institute on Drug Abuse intends to negotiate, evaluate, and award a purchase order on a sole source basis to Corrigall Consulting for professional services in the nicotine and addiction research field in the areas of ligand discovery, disease mechanism discovery and model development, and the translation of preclinical discovery to early-stage development. Specifically, Corrigall Consulting will perform the following: Task 1: Support NIDA efforts in the development of medications for smoking cessation, in the form of a Product Development Partnership or other mechanisms. Assist in the development and editing of text documents for the potential PDP, including position papers, logistical documents, summaries, RFIs, RFAs or other FOAs; assist with the organization and coordination of stakeholder/partner meetings, and contributing to these meetings from the contractor's experience with NIDA/NIH, the nicotine and drug dependence field, and knowledge of activity in medication development for tobacco dependence; participate in management structures, ad hoc or regularly, that would be required to guide the PDP or related ventures (steering and/or oversight committees, project management teams, etc); assist with the development of initiatives that may be required to support the PDP or, in the event that it does not advance, initiatives that would continue to serve NIDA's interests in the development of medications for tobacco dependence; and, develop and advance a proposal for a NIDA-led consensus meeting to review the state of the science with respect to the development of medications for tobacco dependence, recommendations from which could usefully inform the drug discovery process broadly. Such a meeting could be led by the Institute of Medicine with NIDA guidance or, if budgetary constraints are limiting, the meeting could be an NIH State-of-the-Science Conference. Task 2: Monitor, assess and facilitate progress in the National Cooperative Drug Discovery and Development Groups (NCDDDG) Initiative in collaboration with NIDA staff. This initiative currently comprises 4 funded (and 1 pending) cooperative agreement awards within NIDA. Function as coordinator on all NIDA-funded and NIDA co-funded applications, and assist in planning through participation in regular executive committee conference calls with group investigators, participation in annual meetings, and maintaining liaison with NIDA program staff; assist in making the research findings from the groups available more widely, particularly by facilitating the translation of new ligands and novel ligand screening approaches to the broader research community and to the appropriate next stages of research and/or development; and, link activities within the NCDDDG program to other NIDA/NIH funded initiatives as warranted. In particular, the contractor will link emerging developments in the NCDDDG to PDP project management or other NIDA drug discovery activities. Task 3: Advance the agenda for discovery research in the area of nicotine addiction specifically and broadly in drug addiction, and contribute to bridging the gap between mechanism discovery and early stage drug development. The latter dimension is being increasing abandoned by the pharmaceutical industry as a direct result of lack of progress in the former. NIDA has an opportunity to address the loss by targeting funding to specific research areas. Activities by the contractor will include: Maintaining contact with nicotine researchers and scanning the published literature to keep abreast of potential lead developments, such as certain nicotinic cholinergic receptors subtypes, and novel neurochemical mechanisms; working with NIDA staff to develop research initiatives to explore further promising leads, such as novel nicotinic receptor subtypes which are emerging as potentially important candidates in tobacco dependence; publish scientific articles and reviews in target discovery and early translational research, consistent with the contractor's expertise (e.g., Lerman et al, Nature Reviews Drug Discovery 2007; Corrigall, Psychopharmacology 2009); and, encourage researchers to apply fro targeted funding opportunities by personal interactions, through scientific meetings, and by assisting in the organization of workshops. For the contract period, workshops could be held at the Society for Neuroscience in November 2010 and the Wellcome Trust Nicotinic Acetylcholine Receptors meeting in May 2011. The Contractor will report on the progress of all activities at least monthly to the NIDA Project Officer, by telephone conference call, face-to-face meetings, and/or written form. Corrigall Consulting (William Corrigall) was a research scientist at the Addiction Research Foundation/University of Toronto in Toronto (now the Centre for Addiction and Mental Health) for 25 years. During this time he published seminal work on nicotine addiction using laboratory animal models and human experimental paradigms. He is a past president of the Society for Research on Nicotine and Tobacco. In May 2002, Dr. Corrigall joined NIDA as Chief of the Translational Research Branch and Director of NIDA's Nicotine and Tobacco Addiction Program. In this latter role, Dr. Corrigall has implemented major efforts that support NIDA's mission in drug addiction as it relates to tobacco. These include, establishing initiatives in translational (Translating Tobacco Addiction Research to Treatment RFA) and ligand discovery/development research (National Cooperative Drug Discovery Groups for Mood Disorders or Nicotine Addiction RFA), as well as sustaining NIDA's efforts in transdisciplinary tobacco centers (Transdisciplinary Tobacco Use Research Centers RFA). The acquisition is being conducted under simplified acquisition using FAR 13 procedures and is exempt from the requirements of FAR Part 6, Competition Requirement. This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this synopsis. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely with the discretion of the Government. Comments to this announcement, referencing synopsis number NOI1679920 may be submitted to the NIDA, Station Support Simplified Acquisitions Branch, 31 Center Drive, Bldg 31, Room 1B59, Bethesda, MD 20892-2080 and attention Idella Simpson, Contract Specialist, simpsoi@mail.nih.gov, on or before July 27, 2010 3:00pm.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-2/NOI1679920/listing.html)
- Record
- SN02203885-W 20100715/100713234920-5c32014a12da454b104958930799561e (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |